PHAS insider filings

PhaseBio Pharmaceuticals Inc — 50 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2023-05-19. Screen PHAS transaction legs live →

Insider transaction summary — last 90 days

No insider filings (Forms 3/4/5) for PHAS between 2026-08-23 and 2026-11-21. The table below lists the most recent filings on record.

Recent insider filings — PhaseBio Pharmaceuticals Inc

FiledFormInsiderReported transactionsSource
2023-05-194van den Broek Richard — DirectorGrant/award (A): 3,750 · Option exercise (M): 3,750 (derivative) @ $0EDGAR
2023-05-194Thorp Clay — DirectorOption exercise (M): 3,750 · Option exercise (M): 3,750 (derivative) @ $0EDGAR
2023-05-194Humphries William D. — DirectorOption exercise (M): 2,538 · Option exercise (M): 2,538 (derivative) @ $0EDGAR
2023-05-194HARRIGAN EDMUND — DirectorOption exercise (M): 3,750 · Option exercise (M): 3,750 (derivative) @ $0EDGAR
2023-05-194Sapir Alex — DirectorOption exercise (M): 3,750 · Option exercise (M): 3,750 (derivative) @ $0EDGAR
2023-05-194Loewy Caroline M — DirectorOption exercise (M): 3,750 · Option exercise (M): 3,750 (derivative) @ $0EDGAR
2023-05-194Hutson Nancy J — DirectorOption exercise (M): 3,750 · Option exercise (M): 3,750 (derivative) @ $0EDGAR
2022-10-264NEW ENTERPRISE ASSOCIATES 13 LP — 10% owner
NEA Partners 13, Limited Partnership — 10% owner
NEA 13 GP, Ltd — 10% owner
SANDELL SCOTT D — 10% owner
KERINS PATRICK J — 10% owner
BASKETT FOREST — 10% owner
Sale (S): 1,784,109 @ $0.15EDGAR
2022-06-104/AHumphries William D. — DirectorGrant/award (A): 11,842 (derivative) @ $0 · Grant/award (A): 2,538 (derivative) @ $0EDGAR
2022-05-244Arnold Susan Elizabeth — SVP, Technical OperationsGrant/award (A): 10,917 @ $0.68EDGAR
2022-05-244Mow Jonathan P — Chief Executive Officer, DirectorGrant/award (A): 10,918 @ $0.68EDGAR
2022-05-244Burkhardt Glen — SVP of Human ResourcesGrant/award (A): 11,248 @ $0.68 · Sale (S): 11,248 @ $0.79EDGAR
2022-05-244Hanson Kristopher — SVP and General CounselGrant/award (A): 4,831 @ $0.68EDGAR
2022-05-244Birchall Jonathan — Chief Commercial OfficerGrant/award (A): 20,000 @ $0.68EDGAR
2022-05-244Sharp John P — Chief Financial OfficerGrant/award (A): 6,026 @ $0.68EDGAR
2022-05-204Humphries William D. — DirectorGrant/award (A): 17,500 (derivative) @ $0 · Grant/award (A): 3,750 (derivative) @ $0EDGAR
2022-05-204Thorp Clay — DirectorGrant/award (A): 17,500 (derivative) @ $0 · Grant/award (A): 3,750 (derivative) @ $0EDGAR
2022-05-204Hutson Nancy J — DirectorGrant/award (A): 17,500 (derivative) @ $0 · Grant/award (A): 3,750 (derivative) @ $0EDGAR
2022-05-204Sapir Alex — DirectorGrant/award (A): 17,500 (derivative) @ $0 · Grant/award (A): 3,750 (derivative) @ $0EDGAR
2022-05-204Loewy Caroline M — DirectorGrant/award (A): 17,500 (derivative) @ $0 · Grant/award (A): 3,750 (derivative) @ $0EDGAR
2022-05-204HARRIGAN EDMUND — DirectorGrant/award (A): 17,500 (derivative) @ $0 · Grant/award (A): 3,750 (derivative) @ $0EDGAR
2022-05-204van den Broek Richard — DirectorGrant/award (A): 17,500 (derivative) @ $0 · Grant/award (A): 3,750 (derivative) @ $0EDGAR
2022-05-204/AHutson Nancy J — DirectorPurchase (P): 3,000 @ $3.08EDGAR
2022-02-284Burkhardt Glen — VP, Human ResourcesGrant/award (A): 18,750 (derivative) @ $0 · Grant/award (A): 87,500 (derivative) @ $0EDGAR
2022-02-284Sharp John P — Chief Financial OfficerGrant/award (A): 24,750 (derivative) @ $0 · Grant/award (A): 115,500 (derivative) @ $0EDGAR
2022-02-284Birchall Jonathan — Chief Commercial OfficerGrant/award (A): 11,250 (derivative) @ $0 · Grant/award (A): 52,500 (derivative) @ $0EDGAR
2022-02-284Lee John Sang — Chief Medical OfficerGrant/award (A): 24,750 (derivative) @ $0 · Grant/award (A): 115,500 (derivative) @ $0EDGAR
2022-02-284Arnold Susan Elizabeth — SVP, Technical OperationsGrant/award (A): 18,750 (derivative) @ $0 · Grant/award (A): 87,500 (derivative) @ $0EDGAR
2022-02-284Hanson Kristopher — VP, Head of LegalGrant/award (A): 18,750 (derivative) @ $0 · Grant/award (A): 87,500 (derivative) @ $0EDGAR
2022-02-284Mow Jonathan P — Chief Executive Officer, DirectorGrant/award (A): 82,500 (derivative) @ $0 · Grant/award (A): 385,000 (derivative) @ $0EDGAR
2021-11-234Mow Jonathan P — Chief Executive Officer, DirectorGrant/award (A): 5,623 @ $2.01EDGAR
2021-11-234Arnold Susan Elizabeth — SVP, Technical OperationsGrant/award (A): 2,559 @ $2.01EDGAR
2021-11-234Sharp John P — Chief Financial OfficerGrant/award (A): 2,017 @ $2.01EDGAR
2021-11-234Hanson Kristopher — VP, Head of LegalGrant/award (A): 1,545 @ $2.01EDGAR
2021-11-234Burkhardt Glen — VP, Human ResourcesGrant/award (A): 5,766 @ $2.01 · Sale (S): 5,766 @ $2.37EDGAR
2021-11-094Birchall Jonathan — Chief Commercial OfficerGrant/award (A): 250,000 (derivative) @ $3.37EDGAR
2021-11-084Hutson Nancy J — DirectorOption exercise (M): 24,860 @ $2.26 · Option exercise (M): 1,500 @ $3.15 · Option exercise (M): 7,400 @ $3.15 · Option exercise (M): 24,860 (derivative) @ $2.26 · Option exercise (M): 1,500 (derivative) @ $3.15 · Option exercise (M): 7,400 (derivative) @ $3.15EDGAR
2021-11-034Mow Jonathan P — Chief Executive Officer, DirectorOption exercise (M): 20,000 @ $1.24 · Option exercise (M): 20,000 (derivative) @ $1.24EDGAR
2021-11-034Sharp John P — Chief Financial OfficerOption exercise (M): 7,500 @ $1.68 · Option exercise (M): 7,500 (derivative) @ $1.68EDGAR
2021-09-154Humphries William D. — DirectorGrant/award (A): 28,000 (derivative) @ $0EDGAR
2021-09-034/AArnold Susan Elizabeth — VP, Preclinical and ChemOption exercise (M): 4,519 @ $1.74 · Option exercise (M): 4,519 (derivative) @ $0EDGAR
2021-09-034/ASharp John P — Chief Financial OfficerOption exercise (M): 7,500 @ $1.68 · Option exercise (M): 7,500 (derivative) @ $0EDGAR
2021-08-304Mow Jonathan P — Chief Executive Officer, DirectorOption exercise (M): 20,000 @ $1.24 · Option exercise (M): 20,000 (derivative) @ $0EDGAR
2021-08-194Hutson Nancy J — DirectorPurchase (P): 3,000 @ $3.08EDGAR
2021-08-184Thorp Clay — DirectorPurchase (P): 10,000 @ $3EDGAR
2021-08-044Sharp John P — Chief Financial OfficerGrant/award (A): 7,500 @ $1.68EDGAR
2021-07-144Arnold Susan Elizabeth — VP, Preclinical and ChemGrant/award (A): 4,519 @ $1.74EDGAR
2021-06-044Loewy Caroline M — DirectorGrant/award (A): 14,000 (derivative) @ $0EDGAR
2021-06-044Hutson Nancy J — DirectorGrant/award (A): 14,000 (derivative) @ $0EDGAR
2021-06-044Thorp Clay — DirectorGrant/award (A): 14,000 (derivative) @ $0EDGAR

Recent 8-K events — PhaseBio Pharmaceuticals Inc

Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →

FiledFormItems reportedSource
2024-08-158-K8.01 — Other Events
9.01 — Financial Statements and Exhibits
EDGAR
2024-07-128-K1.03 — Bankruptcy or Receivership
8.01 — Other Events
9.01 — Financial Statements and Exhibits
EDGAR
2024-05-168-K8.01 — Other Events
9.01 — Financial Statements and Exhibits
EDGAR
2024-03-128-K1.01 — Entry into a Material Definitive Agreement
8.01 — Other Events
9.01 — Financial Statements and Exhibits
EDGAR
2023-11-298-K8.01 — Other Events
9.01 — Financial Statements and Exhibits
EDGAR
2023-10-038-K5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersEDGAR
2023-09-278-K8.01 — Other Events
9.01 — Financial Statements and Exhibits
EDGAR
2023-08-258-K8.01 — Other Events
9.01 — Financial Statements and Exhibits
EDGAR
2023-06-308-K8.01 — Other Events
9.01 — Financial Statements and Exhibits
EDGAR
2023-05-308-K8.01 — Other Events
9.01 — Financial Statements and Exhibits
EDGAR
Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?ticker=PHAS returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs